Current Editions
An analysis of 11 genetically defined white matter disorders and the modalities being matched to their underlying defects
Product Development
A former agency advisor’s view from inside FDA: What industry often misreads as dysfunction is rooted in caution, independence and process discipline
Guest Commentary
BioCentury identified 172 new targets at AACR 2026
Discovery & Translation
Grace Science says it has been shut out of plausible mechanism framework, denied flexibility on CMC requirements
Regulation
Though unlikely to be adopted, the measure signals strong congressional interest in responding to competition from China
Politics, Policy & Law
Emerging Company Profile
Backed by $16 million in seed funding from Menlo, Aurora is starting with PKU as proving ground
Data Byte
Phase IIa results show high PASI 100 rates for half-life-extended ORKA-001, but durability and quality-of-life data still pending
Two priority review vouchers have sold since the rare pediatric program was extended
Discovery & Translation
BioCentury’s list of 172 new targets from this year’s American Association for Cancer Research abstracts
Plus: BACH1 skews neuronal fate in Down syndrome, and optimized prime editors drive large genomic insertions
How evolving discovery, and a strategic pivot, are driving Syncona’s investments thesis on gene therapies and elsewhere
Deals
Italian company adds another rare disease asset via $1.9B takeout
Seeing potential growth driver, pharma adds ‘NDA-ready’ asset for pediatric neurological disorder
Finance
European investor closes new fund at €215M — a 34% increase over its predecessor — with half earmarked for company creation
Plus: Pair of European microbiome companies draw rounds; Apuri backs Sigmeta; and more
Plus: Data drive follow-ons for Oruka, Veradermics, Intellia; PIPE supports in-licensing deal as Cue welcomes new CEO; and more
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Product Development
Management Tracks
BioCentury ISSN 1097-7201